BR112022005575A2 - Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila - Google Patents
Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilaInfo
- Publication number
- BR112022005575A2 BR112022005575A2 BR112022005575A BR112022005575A BR112022005575A2 BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2 BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2
- Authority
- BR
- Brazil
- Prior art keywords
- enonitrile
- oxetan
- pent
- pyrazolo
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913029P | 2019-10-09 | 2019-10-09 | |
| US201962942877P | 2019-12-03 | 2019-12-03 | |
| PCT/US2020/054809 WO2021072095A1 (en) | 2019-10-09 | 2020-10-08 | Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005575A2 true BR112022005575A2 (pt) | 2022-06-21 |
Family
ID=73030241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005575A BR112022005575A2 (pt) | 2019-10-09 | 2020-10-08 | Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210106583A1 (https=) |
| EP (1) | EP4041240A1 (https=) |
| JP (2) | JP7784995B2 (https=) |
| KR (1) | KR20220079909A (https=) |
| CN (1) | CN115190798A (https=) |
| AU (1) | AU2020363873A1 (https=) |
| BR (1) | BR112022005575A2 (https=) |
| CA (1) | CA3153750A1 (https=) |
| CO (1) | CO2022005949A2 (https=) |
| IL (1) | IL291726A (https=) |
| MX (1) | MX2022004283A (https=) |
| WO (1) | WO2021072095A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202535403A (zh) * | 2023-10-25 | 2025-09-16 | 美商普林斯匹亞生物製藥公司 | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療慢性自發性蕁麻疹 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| CA2971109C (en) | 2014-12-24 | 2024-07-02 | Principia Biopharma Inc. | SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
-
2020
- 2020-10-08 US US17/066,300 patent/US20210106583A1/en not_active Abandoned
- 2020-10-08 BR BR112022005575A patent/BR112022005575A2/pt unknown
- 2020-10-08 EP EP20797943.6A patent/EP4041240A1/en active Pending
- 2020-10-08 AU AU2020363873A patent/AU2020363873A1/en active Pending
- 2020-10-08 WO PCT/US2020/054809 patent/WO2021072095A1/en not_active Ceased
- 2020-10-08 CA CA3153750A patent/CA3153750A1/en active Pending
- 2020-10-08 JP JP2022520968A patent/JP7784995B2/ja active Active
- 2020-10-08 MX MX2022004283A patent/MX2022004283A/es unknown
- 2020-10-08 CN CN202080083113.6A patent/CN115190798A/zh active Pending
- 2020-10-08 KR KR1020227015113A patent/KR20220079909A/ko active Pending
-
2022
- 2022-03-27 IL IL291726A patent/IL291726A/en unknown
- 2022-05-06 CO CONC2022/0005949A patent/CO2022005949A2/es unknown
- 2022-09-30 US US17/957,073 patent/US20230158033A1/en active Pending
-
2025
- 2025-07-18 JP JP2025120944A patent/JP2025157438A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025157438A (ja) | 2025-10-15 |
| IL291726A (en) | 2022-05-01 |
| JP2022552199A (ja) | 2022-12-15 |
| MX2022004283A (es) | 2022-07-12 |
| WO2021072095A1 (en) | 2021-04-15 |
| CA3153750A1 (en) | 2021-04-15 |
| US20230158033A1 (en) | 2023-05-25 |
| EP4041240A1 (en) | 2022-08-17 |
| KR20220079909A (ko) | 2022-06-14 |
| TW202128172A (zh) | 2021-08-01 |
| AU2020363873A1 (en) | 2022-04-14 |
| US20210106583A1 (en) | 2021-04-15 |
| JP7784995B2 (ja) | 2025-12-12 |
| CN115190798A (zh) | 2022-10-14 |
| CO2022005949A2 (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200315B1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| EA202290024A1 (ru) | Способы лечения болезни фабри у пациентов с почечной недостаточностью | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA202190744A1 (ru) | Слитый белок glp1-fc и его конъюгат | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| BR112022005575A2 (pt) | Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila | |
| BR112022009881A2 (pt) | Inibidores de caspase 6 e usos dos mesmos | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| EA202193041A1 (ru) | Многослойные фармацевтические или нутрицевтические твердые лекарственные формы, содержащие производные пиримидина и/или пурина и витамины в, их получение и применение | |
| UA122847C2 (uk) | Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії | |
| CL2022003477A1 (es) | Compuesto de alquenilpirimidina, método de preparación del mismo y aplicación del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |